HealthCare Global Enterprises (HCG) Q3 25/26 earnings summary

Executive summary

• Focus remains on strengthening the core oncology platform, driving clinical and financial consistency, and expanding through brownfield and selective greenfield projects.

• Clinical excellence demonstrated with advanced treatments and technology, including CyberKnife radiosurgery, robotic surgeries, and MR-LINAC introduction in North Bangalore.

• Senior leadership team strengthened across key functions; new HCG Employee Stock Option Scheme 2026 introduced, pending shareholder approval.

Financial highlights

• Q3FY26 consolidated revenue reached INR 6,331mn, up 13% year-over-year; nine months revenue was INR 18,931mn, up 15% year-over-year.

• Adjusted EBITDA for Q3FY26 was INR 1,108mn, up 20% year-over-year, with margin expansion to 17.5%.

• ARPP (excluding fertility) for Q3FY26 was INR 84,208, up 5% year-over-year; volumes (excluding fertility) for Q3FY26 were 80,024, up 8% year-over-year.

• Standalone net loss for Q3FY26 was INR 118 lakhs, with consolidated net loss of INR 943 lakhs attributable to owners, mainly due to exceptional labor code-related costs.

• Exceptional items in Q3FY26: INR 786 lakhs (standalone) and INR 1,267 lakhs (consolidated) due to regulatory-driven labor code changes.

Outlook and guidance

• Maintains guidance of 15%+ annual growth, with margin trajectory expected to rise to 23%-24% over the next three to four years.

• North Bangalore Greenfield Hospital to open by end of Q4FY26, featuring MR-LINAC technology.

• Company will continue to monitor regulatory developments regarding labor codes and adjust accounting as needed.

• Volume growth of about 10% and ARPP growth of about 5% expected to drive future sales.